2026-09-30T13:00:25.000Z · 3 days ago Silo Pharma’s QwikAgents expands AI agent platform with Nvidia model support
Sep 30, 2026, 8:50 AM EDT · 3 days ago Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
2026-09-18T13:10:37.000Z · 15 days ago Silo Pharma receives U.S. patent allowance for SPC-15 PTSD treatment
Sep 18, 2026, 8:50 AM EDT · 15 days ago Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Sep 9, 2026, 9:15 AM EDT · 24 days ago Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
2026-08-18T20:20:47.000Z · 6 weeks ago Silo Pharma receives notice of allowance from CIPO for PTSD treatment
Aug 18, 2026, 4:15 PM EDT · 6 weeks ago Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Aug 6, 2026, 8:50 AM EDT · 1 month ago Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
2026-07-24T20:10:24.000Z · 2 months ago Silo Pharma files to sell 1.91M shares of common stock for holders
Jul 21, 2026, 8:55 AM EDT · 2 months ago Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Jul 14, 2026, 8:55 AM EDT · 2 months ago Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
2026-07-10T12:16:17.000Z · 2 months ago Silo Pharma prices $11.7M at-the-market offering at $6.45 per share
Jul 10, 2026, 8:00 AM EDT · 2 months ago Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Jul 7, 2026, 8:11 AM EDT · 2 months ago Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
2026-06-29T20:50:29.000Z · 3 months ago Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery
Jun 29, 2026, 4:15 PM EDT · 3 months ago Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
2026-06-23T15:29:15.000Z · 3 months ago Silo Pharma reports positive stability data for stress treatment SPC-15
Jun 23, 2026, 8:17 AM EDT · 3 months ago Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
2026-06-18T12:33:09.000Z · 3 months ago Silo Pharma regains compliance with Nasdaq min bid price requirement
Jun 18, 2026, 8:12 AM EDT · 3 months ago Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-05-07T18:37:18.000Z · 4 months ago Silo Pharma files provisional patent for ibogaine-based therapeutics
May 7, 2026, 8:05 AM EDT · 4 months ago Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
Apr 29, 2026, 9:08 AM EDT · 5 months ago Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
2026-04-22T21:10:17.000Z · 5 months ago Silo Pharma expands into AI technology with Qwikagents asset purchase
Apr 22, 2026, 4:15 PM EDT · 5 months ago Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Apr 6, 2026, 4:15 PM EDT · 6 months ago Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
Feb 18, 2026, 8:28 AM EST · 7 months ago Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
Dec 30, 2025, 8:05 AM EST · 9 months ago Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
Nov 17, 2025, 8:05 AM EST · 10 months ago Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
Oct 29, 2025, 8:25 AM EDT · 11 months ago Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
Oct 23, 2025, 8:45 AM EDT · 11 months ago Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Oct 8, 2025, 8:45 AM EDT · 12 months ago Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
Oct 6, 2025, 8:10 AM EDT · 12 months ago Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
Oct 1, 2025, 4:20 PM EDT · 1 year ago Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Sep 30, 2025, 8:02 AM EDT · 1 year ago Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Sep 16, 2025, 8:11 AM EDT · 1 year ago Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
Sep 9, 2025, 9:10 AM EDT · 1 year ago Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
Sep 3, 2025, 8:25 AM EDT · 1 year ago Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
Aug 21, 2025, 2:00 PM EDT · 1 year ago Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
Aug 19, 2025, 8:05 AM EDT · 1 year ago Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
Aug 5, 2025, 8:32 AM EDT · 1 year ago Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
Jul 16, 2025, 8:45 AM EDT · 1 year ago Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
Jul 7, 2025, 8:15 AM EDT · 1 year ago Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Jun 25, 2025, 8:38 AM EDT · 1 year ago Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025, 8:27 AM EDT · 1 year ago Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
Jun 11, 2025, 9:00 AM EDT · 1 year ago Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
Jun 5, 2025, 9:15 AM EDT · 1 year ago Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
May 21, 2025, 8:55 AM EDT · 1 year ago Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 14, 2025, 4:07 PM EDT · 1 year ago Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
May 14, 2025, 8:40 AM EDT · 1 year ago Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Apr 30, 2025, 8:11 AM EDT · 1 year ago Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Apr 28, 2025, 7:50 AM EDT · 1 year ago Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
Mar 26, 2025, 8:40 AM EDT · 1 year ago Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Feb 26, 2025, 1:30 PM EST · 1 year ago Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
Feb 18, 2025, 8:50 AM EST · 1 year ago Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Feb 11, 2025, 7:45 AM EST · 1 year ago Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Jan 22, 2025, 8:29 AM EST · 1 year ago Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment